Dermatology facing autoinflammatory syndrome

Romanian Journal of Morphology and Embryology

Volumn 56, Issue 1, 2015, Pages 7-14

  Alecu, Mihail ^a,b   Coman, Gabriela ^a   Muşetescu, Alina ^a,b   Cojoacă, Marian Emanuel ^b   Coman, Oana Andreia ^a,c  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b TITU MAIORESCU UNIVERSITY   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Autoinflammatory syndrome; Pathogenetic mechanism; Skin disease

Indexed keywords

EQUUS ASINUS;

COMPLEMENT; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT PROTEIN;

ACNE VULGARIS; CHEMISTRY; DERMATOLOGY; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; PYODERMA GANGRENOSUM; SKIN; SKIN DISEASE;

ACNE VULGARIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COMPLEMENT SYSTEM PROTEINS; DERMATOLOGY; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1BETA; MACROPHAGES; MUTATION; PHENOTYPE; PYODERMA GANGRENOSUM; RECOMBINANT PROTEINS; SKIN; SKIN DISEASES; SKIN PHYSIOLOGICAL PHENOMENA;

EID: 84925310728     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. [1] Siegal S. Benign paroxysmal peritonitis. Ann Intern Med, 1945, 23(1):1–21.
2. [2] Siegal S. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell, 1997, 90(4): 797–806.
3. [3] Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Horwitz ME, Mansfield E, Holland SM, O’Shea JJ, Rosenberg HF, Malech HL, Kastner DL. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood, 2000, 95(10):3223–3231.
4. [4] Matzner Y, Abedat S, Shapiro E, Eisenberg S, Bar-Gil-Shitrit A, Stepensky P, Calco S, Azar Y, Urieli-Shoval S. Expression of the familial Mediterranean fever gene and activity of the C5a inhibitor in human primary fibroblast cultures. Blood, 2000, 96(2):727–731.
5. [5] Ozgurede VU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol, 2012, 167(3):382–390.
6. [6] Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore), 1994, 73(3):133–144.
7. [7] Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, de Jong JG, Beckmann JS, van der Meer JW, Delpech M. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet, 1999, 22(2):178–181.
8. [8] Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet, 2001, 29(3):301–305.
9. [9] Toitou I, Koné-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol, 2008, 22(5):811–829.
10. [10] Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. Moll Cell, 2002, 10(2):417–426.
11. [11] McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo AM, Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R, Kumarajeewa TR, Cooper SM, Vella JP, Amos CI, Mulley J, Quane KA, Molloy MG, Ranki A, Powell RJ, Hitman GA, O’Shea JJ, Kastner DL. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell, 1999, 97(1):133–144.
12. [12] Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, Kastner DL, Screaton GR, Siegel RM. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood, 2006, 108(4):1320–1327.
13. [13] Stojanov S, Lapidus S, Chitkara P, Feder H, Salazar JC, Fleisher TA, Brown MR, Edwards KM, Ward MM, Colbert RA, Sun HW, Wood GM, Barham BK, Jones A, Aksentijevich I, Goldbach-Mansky R, Athreya B, Barron KS, Kastner DL. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A, 2011, 108(17):7148–7153.
14. [14] Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEnvoy MT. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc, 1997, 72(7):611–615.
15. [15] Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, Chamaillard M, Zouali H, Thomas G, Hugot JP. CARD15 mutations in Blau syndrome. Nat Genet, 2001, 29(1):19–20.
16. [16] Bellanti AJ, Benavides G. Autoinflammatory disorders caused by self direct innate immune injury. In: Bellanti JA (ed). Immunology IV: clinical applications in health and disease. Care Press, Bethesda, Maryland, 2012, 19:791–798.
17. [17] Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol, 2009, 27:621–668.
18. [18] Kanazawa N, Furukawa F. Autoinflammatory syndromes with a dermatological perspective. J Dermatol, 2007, 34(9):601–618.
19. [19] Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol, 2002, 14(5):584–552.
20. [20] Bellanti JA, Escobar-Gutierrez A, Oppenheim JJ. Cytokines, chemokines and immune system. In: Bellanti JA (ed). Immunology IV: clinical applications in health and disease. Care Press, Bethesda, Maryland, 2012, 9:313–323.
21. [21] Pétrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol, 2007, 19(6):615–622.
22. [22] Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol, 2009, 27:519–550.
23. [23] Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol, 2011, 167(3):391–404.
24. [24] Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol, 2009, 124(6):1141–1149; quiz 1150–1151.
25. [25] Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, Kastner DL. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A, 2003, 100(23):13501–13506.
26. [26] Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgård U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med, 2009, 360(23):2426–2437.
27. [27] Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med, 2007, 356(12): 1216–1225.
28. [28] Kanazawa N. Sarcoidosis and autoinflammation. Inflamm Regen, 2011, 31(1):66–71.
29. [29] Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Müslümanoğlu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A, 2003, 100(22):12966–12971.
30. [30] Ueki Y, Lin CY, Senoo M, Ebihara T, Agata N, Onji M, Saheki Y, Kawai T, Mukherjee PM, Reichenberger E, Olsen BR. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 “cherubism” mice. Cell, 2007, 128(1):71–83.
31. [31] Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G, Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science, 1999, 286(5446): 1957–1959.
32. [32] De Sanctis S, Nozzi M, Del Torto M, Scardapane A, Gaspari S, de Michele G, Breda L, Chiarelli F. Autoinflammatory syndromes: diagnosis and management. Ital J Pediatr, 2010, 36:57.
33. [33] Galon J, Aksentijevich I, McDermott MF, O’Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol, 2000, 12(4):479–486.
34. [34] Kastner DL, O’Shea JJ. A fever gene comes in from the cold. Nat Genet, 2001, 29(3):241–242.
35. [35] McDermott MF, Aksentijevich I. The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol, 2002, 2(6):511–516.
36. [36] Galeazzi M, Gasbarrini G, Ghirardello A, Grandemange S, Hoffman HM, Manna R, Podswiadek M, Punzi L, Sebastiani GD, Touitou I, Doria A. Autoinflammatory syndromes. Clin Exp Rheumatol, 2006, 24(1 Suppl 40):S79–S85.
37. [37] McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med, 2006, 3(8):e297.
38. [38] Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges, 2011, 9(3):232–246.
39. [39] Berg S, Fasth A. Autoinflammatory disorders in primary immunodeficiency disease. In: Rezaei N, Aghamohammadi A, Notarangelo LD (eds). Primary immunodeficiency diseases: definition, diagnosis, and management. 1st edition, Springer, Berlin–Heidelberg, 2007, 7:215–233.
40. [40] Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly, 2012, 142:w13590.
41. [41] Brau-Javier CN, Gonzales-Chavez J, Toro JR. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Arch Dermatol, 2012, 148(3):301–304.
42. [42] Stoevesandt J, Morbach H, Martin TM, Zierhut M, Girschick H, Hamm H. Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. Pediatr Dermatol, 2010, 27(1):69–73.
43. [43] Hawkins PN1, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle–Wells syndrome and response to anakinra. Arthritis Rheum, 2004, 50(2):607–612.
44. [44] Barzilai A, Langevitz P, Goldberg I, Kopolovic J, Livneh A, Pras M, Trau H. Erysipelas-like erythema of familial Mediterranean fever: clinicopathologic correlation. J Am Acad Dermatol, 2000, 42(5 Pt 1):791–795.
45. Padeh S. Pediatric fever syndromes. Pediatr Clin North Am, 2005, 52(2):577–609, vii.
46. [46] Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol, 2009, 161(5):1199–1201.
47. [47] Noschella SL, Davis MDP. Neutrophilic dermatoses in dermatology. In: Bolognia JL, Joriyyo J, Rapini R (eds). Dermatology. 2nd edition, Mosby–Elsevier, St. Louis, 2008, 27:379–393.
48. [48] Chen PD, Yu SL, Chen S, Weng XH. Retrospective study of 61 patients with adult-onset Still’s disease admitted with fever of unknown origin in China. Clin Rheumatol, 2012, 31(1):175–181.
49. [49] Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D, Senécal JL, Yeadon C, Esdaile JM. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore), 1991, 70(2):118–136.
50. [50] Cohen PR, Kurzrock R. Sweet’s syndrome revised: a review of disease concepts. Int J Dermatol, 2003, 42(10):761–768.
51. [51] Kawakami T, Ohashi S, Kawa Y, Takahama H, Ito M, Soma Y, Mizoguchi M. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active Behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol, 2004, 140(5): 570–574.
52. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis, 2005, 64(Suppl 2): ii30–ii36.
53. [53] Plant D, Lear J, Marsland A, Worthington J, Griffiths CE. CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis. Br J Dermatol, 2004, 151(3):675–678.
54. [54] Day TG, Ramanan AV, Hinks A, Lamb R, Packham J, Wise C, Punaro M, Donn RP. Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. Arthritis Rheum, 2008, 58(7):2142–2146.
55. [55] Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, Young HS, Bradburn P, Thomson W, Silman AJ, Bruce IN. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis, 2008, 67(5):677–682.
56. [56] Jin Y, Riccardi SL, Gowan K, Fain PR, Spritz RA. Finemapping of vitiligo susceptibility loci on chromosomes 7 and 9 and interactions with NLRP1 (NALP1). J Invest Dermatol, 2010, 130(3):774–783.
57. [57] Magitta NF, Bøe Wolff AS, Johansson S, Skinningsrud B, Lie BA, Myhr KM, Undlien DE, Joner G, Njølstad PR, Kvien TK, Førre Ø, Knappskog PM, Husebye ES. A coding polymorphism in NALP1 confers risk for autoimmune Addison’s disease and type 1 diabetes. Genes Immun, 2009, 10(2):120–124.
58. [58] Watanabe H, Gaide O, Pétrilli V, Martinon F, Contassot E, Roques S, Kummer JA, Tschopp J, French LE. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol, 2007, 127(8):1956–1963.
59. [59] Kanazawa N. Nakajo–Nishimura syndrome: an autoinflammatory disorder showing pernio-like rashes and progressive partial lipodystrophy. Allergol Int, 2012, 61(2):197–206.
60. [60] Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell, 2010, 140(6):784–790.
61. [61] Yao Q, Furst DE. Autoinflammatory diseases: an update of clinical and genetic aspects. Rheumatology (Oxford), 2008, 47(7):946–951.
62. [62] Rigante D, Cantarini L. Monogenic autoinflammatory syndromes at the dermatological level. Arch Dermatol Res, 2011, 303(6):375–380.
63. [63] Tunca M, Odogan M. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy, 2005, 4(1):77–80.
64. [64] Sarrauste de Menthière C, Terrière S, Pugnère D, Ruiz M, Demaille J, Touitou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res, 2003, 31(1):282–285.
65. [65] Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP, Kastner DL. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell, 2003, 11(3):591–604.
66. [66] Houten SM, Kuis W, Duran M, de Koning TJ, van Royen-Kerkhof A, Romeijn GJ, Frenkel J, Dorland L, de Barse MM, Huijbers WA, Rijkers GT, Waterham HR, Wanders RJ, Poll-The BT. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet, 1999, 22(2):175–177.
67. [67] Drenth JP, Göertz J, Daha MR, van der Meer JW. Immunoglobulin D enhances the release of tumor necrosis factoralpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology, 1996, 88(3):355–362.
68. [68] Aksentijevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner DL. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum, 2007, 56(4):1273–1285.
69. [69] Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott MF. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum, 2002, 46(9):2445–2452.
70. [70] Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Gen, 2002, 11(8):961–969.
71. [71] Smith EJ, Allantaz F, Bennett L, Zhang D, Gao X, Wood G, Kastner DL, Punaro M, Aksentijevich I, Pascual V, Wise CA. Clinical, molecular, and genetic characteristics of PAPA syndrome: a review. Curr Genomics, 2010, 11(7):519–527.
72. [72] Verma D, Lerm M, Blomgran Julinder R, Eriksson P, Söderkvist P, Särndahl E. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases? Arthritis Rheum, 2008, 58(3):888–894.
73. [73] Sugiura T, Kawaguchi Y, Fujikawa S, Hirano Y, Igarashi T, Kawamoto M, Takagi K, Hara M, Kamatani N. Familial Mediterranean fever in three Japanese patients, and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. Mod Rheumatol, 2008, 18(1):57–59.
74. [74] Ben-Chetrit E, Peleg H, Aamar S, Heyman SN. The spectrum of MEFV clinical presentations–is it familial Mediterranean fever only? Rheumatology (Oxford), 2009, 48(11):1455–1459.
75. [75] Minkis K, Aksentijevich I, Goldbach-Mansky R, Magro C, Scott R, Davis JG, Sardana N, Herzog R. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol, 2012, 148(6):748–752.
76. [76] Brau-Javier CN, Gonzales-Chavez J, Toro JR. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Arch Dermatol, 2012, 148(3):301–304.
77. [77] Gattorno M, Federici S, Pelagatti MA, Caorsi R, Brisca G, Malattia C, Martini A. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol, 2008, 28(Suppl 1):S73–S83.
78. [78] Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med, 2007, 146(11):825–826
79. [79] Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford), 2003, 42(2):235–239.
80. [80] Caorsi R, Federici S, Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev, 2012, 12(1):81–86.